Rallybio Corporation (NASDAQ:RLYB) Given Consensus Recommendation of “Reduce” by Analysts

Shares of Rallybio Corporation (NASDAQ:RLYB) have received an average recommendation of “Reduce” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a hold rating on the company.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research note on Monday, December 29th.

Rallybio Price Performance

NASDAQ RLYB traded down $0.18 on Friday, reaching $8.26. The company had a trading volume of 4,697 shares, compared to its average volume of 135,119. Rallybio has a 1 year low of $1.76 and a 1 year high of $11.49. The firm has a 50-day moving average of $6.91 and a 200-day moving average of $5.74. The firm has a market capitalization of $43.69 million, a PE ratio of -3.19 and a beta of -1.13.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.10 million. As a group, sell-side analysts expect that Rallybio will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RLYB. Renaissance Technologies LLC grew its stake in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after purchasing an additional 120,892 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after purchasing an additional 373,821 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after buying an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares in the last quarter. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.